I-Brand Institute ibhengeze ubambiswano lwayo oluyimpumelelo kunye neGlobal Blood Therapeutics (GBT) ekubizeni unyango oluvunyiweyo lweEMA, i-OXBRYTA, eboniswe kunyango lwe-anemia ye-hemolytic ngenxa yesifo se-sickle cell (SCD) kwizigulana zabantu abadala kunye nabantwana abaneminyaka eyi-12 ubudala nangaphezulu. i-monotherapy okanye idibene ne-hydroxycarbamide (i-hydroxyurea). Oku kulandela imvume ye-FDA kunye neMpilo yaseCanada yonyango ngo-2019.
"Iqela lonke leBrand Institute kunye neDrug Safety Institute livuyisana neGlobal Blood Therapeutics kwimvume ye-FDA ye-OXBRYTA," watsho uSihlalo we-Brand Institute kunye ne-CEO, uJames L. Dettore. "Olu nyango luguqulayo lunamandla okwenza umahluko omkhulu kwabo baseYurophu baphila nesi sifo siqobayo."
I-OXBRYTA yiyeza lokuqala elivunyiweyo eYurophu elithintela ngokuthe ngqo i-sickle hemoglobin (HbS) i-polymerization, isiseko se-molecular yokugula kunye nokutshatyalaliswa kweeseli ezibomvu zegazi kwi-SCD. I-OXBRYTA isebenza ngokwandisa i-hemoglobin ehambelana neoksijini. Ekubeni i-oksijini ye-hemoglobin ene-oksijini ayinayo i-polymerize, i-OXBRYTA inqanda i-cyle hemoglobin polymerization kunye nesiphumo sokugula kunye nokutshatyalaliswa kweeseli ezibomvu zegazi.
"Sikholelwa ukuba igama le-brand ye-OXBRYTA lifanelekile kwimveliso," waqhubeka uDettore. "Ukongeza kwisimamva esinxulumene 'neoksijini', sibhekisa kwindlela yokusebenza kwemveliso, igama lineempawu ezininzi kunye neempawu esizisukelayo xa sivelisa igama elitsha loxubo mayeza."
INTO ONOKUYITHATHA KWELI NQAKU:
- Brand Institute announced its successful partnership with Global Blood Therapeutics (GBT) in naming their EMA-approved therapy, OXBRYTA, indicated for the treatment of hemolytic anemia due to sickle cell disease (SCD) in adult and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide (hydroxyurea).
- OXBRYTA is the first medicine approved in Europe that directly inhibits sickle hemoglobin (HbS) polymerization, the molecular basis of sickling and destruction of red blood cells in SCD.
- Since oxygenated sickle hemoglobin does not polymerize, OXBRYTA inhibits sickle hemoglobin polymerization and the resultant sickling and destruction of red blood cells.
